Madrigal Pharmaceuticals
MDGL
138 hedge funds and large institutions have $858M invested in Madrigal Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 22 closing their positions.
83% more call options, than puts
Call options by funds: $20.5M | Put options by funds: $11.2M
9% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 22
5% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 40
1.41% less ownership
Funds ownership: 71.62% → 70.21% (-1.4%)
1% less funds holding
Funds holding: 140 → 138 (-2)
28% less capital invested
Capital invested by funds: $1.2B → $858M (-$342M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$13.4M |
| 2 |
AC
Armistice Capital
New York
|
+$8.97M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$8.75M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$8.09M |
| 5 |
PA
Perceptive Advisors
New York
|
+$6.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$64.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.59M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.54M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$5.18M |
| 5 |
LC
L1 Capital
Melbourne VIC 3000,
Australia
|
-$3.48M |
MDGL Hedge Fund Activity: Q2 2022 in Review
138 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2022, worth a combined $858M — down 28% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MDGL positions and 22 closed out — a net gain of 2 holders — while 42 added to existing stakes and 40 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $13.4M. The largest seller was Wellington Management Group, cutting an estimated $64.5M.
- 138 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2022, down from 140 in Q1 2022.
- Funds reported $858M of Madrigal Pharmaceuticals stock for Q2 2022, down 28% quarter-over-quarter.
- 24 funds opened new Madrigal Pharmaceuticals positions in Q2 2022 and 22 closed out, a net change of +2 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2022 was Jennison Associates, an estimated $13.4M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2022 was Wellington Management Group, an estimated $64.5M sold.
Based on aggregated 13F filings for Q2 2022.